• 1
    Dattoli M, Wallner K, Sorace R, et al. 103Pd brachytherapy and external beam irradiation for clinically localized, high-risk prostate carcinoma. Int J Radiat Oncol Biol Phys. 1997; 39: 776-777.
  • 2
    Ragde H, Blasko JC, Grimm PD, et al. Brachytherapy for clinically localized prostate cancer: results at 7- and 8-year follow-up. Semin Surg Oncol. 1997; 13: 438-443.
  • 3
    Stone NN, Stock RG. Prostate brachytherapy: treatment strategies. J Urol. 1999; 162: 421-426.
  • 4
    Lee WR, DeSilvio M, Lawton C, et al. A phase II study of external beam radiotherapy combined with permanent source brachytherapy for intermediate-risk, clinically localized adenocarcinoma of the prostate: preliminary results of RTOG P-0019. Int J Radiat Oncol Biol Phys. 2006; 64: 804-809.
  • 5
    Lee WR, Bae K, Lawton C, et al. Late toxicity and biochemical recurrence after external-beam radiotherapy combined with permanent-source prostate brachytherapy: analysis of Radiation Therapy Oncology Group study 0019. Cancer. 2007; 109: 1506-1512.
  • 6
    Sylvester JE, Grimm PD, Blasko JC, et al. 15-Year biochemical relapse free survival in clinical stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy; Seattle experience. Int J Radiat Oncol Biol Phys. 2007; 67: 57-64.
  • 7
    Dattoli M, Wallner K, True L, et al. Long-term outcomes after treatment with brachytherapy and supplemental conformal radiation for prostate cancer patients having intermediate and high-risk features. Cancer. 2007; 110: 551-555.
  • 8
    Critz FA, Williams WH, Levinson AK, et al. Simultaneous irradiation for prostate cancer: intermediate results with modern techniques. J Urol. 2000; 164( 3 pt 1): 738-741.
  • 9
    Merrick GS, Butler WM, Wallner KE, et al. Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2005; 61: 32-43.
  • 10
    Singh AM, Gagnon G, Collins B, et al. Combined external beam radiotherapy and Pd-103 brachytherapy boost improves biochemical failure free survival in patients with clinically localized prostate cancer: results of a matched pair analysis. Prostate. 2005; 62: 54-60.
  • 11
    Stock RG, Cahlon O, Cesaretti JA, et al. Combined modality treatment in the management of high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2004; 59: 1352-1359.
  • 12
    D'Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW. 6-Month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA. 2004; 292: 821-827.
  • 13
    D'Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA. 2008; 299: 289-295.
  • 14
    Denham JW, Steigler A, Lamb DS, et al. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol. 2005; 6: 841-850.
  • 15
    McGowan D, Hunt D, Jones C, et al. Short term androgen deprivation prior to and during radiation therapy improves overall survival in patients with t1b-t2b adenocarcinoma of the prostate and PSA ≤20: initial results of RTOG 94-08 [abstract]. ASTRO 2009.
  • 16
    Stock RG, Stone NN, Cesaretti JA. Prostate-specific antigen bounce after prostate seed implantation for localized prostate cancer: descriptions and implications. Int J Radiat Oncol Biol Phys. 2003; 56: 448-453.
  • 17
    Cavanagh W, Blasko JC, Grimm PD, et al. Transient elevation of serum prostate-specific antigen following I/Pd brachytherapy for localized prostate cancer. Semin Urol Oncol. 2000; 18: 160-165.
  • 18
    Critz FA, Williams WH, Benton JB, et al. Prostate specific antigen bounce after radioactive seed implantation followed by external beam radiation for prostate cancer. J Urol. 2000; 163: 1085-1089.
  • 19
    Thames H, Kuban D, Levy L, et al. Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995. Int J Radiat Oncol Biol Phys. 2003; 57: 929-943.
  • 20
    Roach M III, Hanks G, Thames H Jr, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006; 65: 965-974.
  • 21
    Hurwitz MD, Halabi S, Ou SS, et al. Combination external beam radiation and brachytherapy boost with androgen suppression for treatment of intermediate-risk prostate cancer: an initial report of CALGB 99809. Int J Radiat Oncol Biol Phys. 2008; 72: 814-819.
  • 22
    Benoit RM, Naslund MJ, Cohen JK. Complications after prostate brachytherapy in the Medicare population. Urology. 2000; 55: 91-96.
  • 23
    Zelefsky MJ, Fuks Z, Wolfe T, et al. Locally advanced prostatic cancer: long-term toxicity outcome after 3-dimensional conformal radiation therapy—a dose-escalation study. Radiology. 1998; 209: 169-174.
  • 24
    Zelefsky MJ, Hollister T, Raben A, et al. Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys. 2000; 47: 1261-1266.
  • 25
    Giordano SH, Lee A, Kuo YF, et al. Late gastrointestinal toxicity after radiation for prostate cancer. Cancer. 2006; 107: 423-432.